Volume 29, Number 9—September 2023
Research
Temporally Associated Invasive Pneumococcal Disease and SARS-CoV-2 Infection, Alaska, USA, 2020–2021
Katherine Newell
, Marc Fischer, Stephanie Massey, Laurie Orell, Jonathan Steinberg, Megan Tompkins, Louisa Castrodale, and Joseph McLaughlin
, Marc Fischer, Stephanie Massey, Laurie Orell, Jonathan Steinberg, Megan Tompkins, Louisa Castrodale, and Joseph McLaughlin
Table 2
Characteristics of patients who had IPD temporally associated with a SARS-CoV-2 infection, compared with patients who had IPD alone, Alaska, USA, 2020–2021*
| Characteristic | IPD patients with SARS-CoV-2 infection, no. (%), n = 55 | IPD patients without SARS-CoV-2 infection, no. (%), n = 216 | p value† |
|---|---|---|---|
| Sex | 0.29 | ||
| M | 31 (56) | 141 (65) | |
| F |
24 (44) |
75 (35) |
|
| Age, y | 0.90 | ||
| <20 | 1 (2) | 6 (3) | |
| 20–39 | 12 (22) | 57 (26) | |
| 40–59 | 25 (46) | 93 (43) | |
| ≥60 |
17 (31) |
60 (28) |
|
| Race | 0.98 | ||
| Alaska Native/American Indian | 29 (53) | 117 (54) | |
| White | 16 (30) | 62 (29) | |
| Other/unknown |
10 (18) |
37 (17) |
|
| Region | 0.70 | ||
| Anchorage | 28 (51) | 111 (51) | |
| Interior | 7 (13) | 31 (14) | |
| Gulf | 4 (7) | 16 (7) | |
| Matanuska-Susitna | 5 (9) | 15 (7) | |
| Northern | 2 (4) | 20 (9) | |
| Southeast | 2 (4) | 7(3) | |
| Southwest |
7 (13) |
16 (7) |
|
| Underlying medical condition | 1.0 | ||
| ≥1 | 44 (80) | 175 (81) | |
| None |
11 (20) |
41 (19) |
|
| Seasonality | <0.01 | ||
| Summer, June–August | 10 (18) | 54 (25) | |
| Fall, September–December | 37 (67) | 76 (35) | |
| Winter, December–February | 5 (9) | 27 (13) | |
| Spring, March–May |
3 (6) |
59 (27) |
|
| Person experiencing homelessness | 0.01 | ||
| Yes | 19 (34) | 39 (18) | |
| No |
36 (66) |
177 (82) |
|
| Pneumococcal vaccine received | 0.80 | ||
| PCV13 | 5 (9) | 26 (12) | |
| PPSV23 | 17 (31) | 70 (32) | |
| Both | 2 (4) | 13 (6) | |
| Neither |
31 (56) |
107 (50) |
|
| COVID-19 vaccine received | 0.09 | ||
| Fully vaccinated | 9 (16) | 43 (20) | |
| Not fully vaccinated | 28 (51) | 59 (27) | |
| Not eligible‡ |
18 (33) |
114 (53) |
|
| Clinical syndrome§ | <0.01 | ||
| Pneumonia | 46 (84) | 155 (72) | |
| Bacteremia without source | 9 (16) | 43 (20) | |
| Other |
2 (4) |
49 (23) |
|
| Hospitalized | 0.26 | ||
| Yes | 49 (89) | 179 (83) | |
| No/unknown |
6 (11) |
37 (17) |
|
| Died | <0.01 | ||
| Yes | 9 (16) | 9 (4) | |
| No | 46 (84) | 196 (91) | |
| Unknown | 0 | 11 (5) |
*IPD, invasive pneumococcal disease; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine. †By χ2 test. ‡Not eligible for COVID-19 vaccination at the time of IPD detection based on Alaska’s initial COVID-19 vaccine introduction schedule. Not included in χ2 calculation. §Clinical syndromes are not mutually exclusive.
Page created: July 20, 2023
Page updated: August 20, 2023
Page reviewed: August 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.